logo

Synthetic Biologics Inc. (SYN)



Trade SYN now with
  Date
  Headline
7/1/2019 7:11:43 AM Synthetic Biologics Regains Compliance With NYSE American Continued Listing Standards
5/8/2019 4:13:47 PM Synthetic Biologics Q1 Loss/share $0.25 Vs. Loss $0.65 Year Ago
1/3/2019 7:09:01 AM Synthetic Biologics Announces First Two Patients Enrolled In Phase 2b Investigator-Sponsored Clinical Study Of SYN-010
12/4/2018 1:08:52 PM Orchestra BioMed Appoints Evan Ballantyne As CFO
11/21/2018 7:03:00 AM Synthetic Biologics Announces Positive Outcome Of End-of-Phase 2 Meeting With FDA On SYN-004 Development
10/15/2018 2:01:17 PM Synthetic Biologics Closes $18.64 Mln Public Offering
10/11/2018 9:08:55 AM Synthetic Biologics Prices $18 Mln Public Offering
9/6/2018 7:20:17 AM Synthetic Biologics Enters Agreement With Cedars-Sinai Medical Center For Phase 2 Clinical Study Of SYN-010
8/1/2018 5:09:46 PM Synthetic Biologics Announces Reverse Stock Split Of Common Stock At Ratio Of 1:35 Shares
5/22/2018 7:03:48 AM Synthetic Biologics Announces Acceptance Of Compliance Plan By NYSE American
2/26/2016 8:43:47 AM FBR Capital Markets Initiates Synthetic Biologics Inc. (SYN) At Outperform With $10 Price Target
10/13/2015 7:50:50 AM RBC Capital Markets Starts Synthetic Biologics Inc. (SYN) At Outperform With $2.27 Price Target